Payment overview · 2025
General Payments
$892.26
33 reported records · 14 companies
Healthcare provider profile · identity verified
James Clyde Lamon, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MOULTRIE, GA · NPI 1013019033
Verified facts
What the public records show
CMS Open Payments records show James Clyde Lamon, MD received $892.26 in general payments during 2025 across 33 reported records.
Sekisui Diagnostics LLC accounted for 30.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Kerendia, Linzess, Mounjaro, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 614 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 265 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 301 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 574 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 315 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sekisui Diagnostics LLC | Unresolved — no canonical attribution shown | $275.00 | 30.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $159.65 | 17.9% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $84.50 | 9.5% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $60.70 | 6.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $56.11 | 6.3% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $48.40 | 5.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $39.21 | 4.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.32 | 4.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.59 | 3.8% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.64 | 2.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.07 | 2.5% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.11 | 2.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.69 | 2.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.27 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $617.26 | 32 |
| Gift | $275.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $97.25 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $84.50 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $62.40 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $62.40 | 4 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $60.70 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $48.40 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $40.80 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $37.32 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $23.64 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $23.06 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $18.11 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.69 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 109 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 315 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 614 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 109 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 188 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 574 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 265 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
109 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
188 | 55 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
145 | 23 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
614 | 135 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
109 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
53 | 50 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
265 | 59 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
301 | 84 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
574 | 82 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
89 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
315 | 66 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1335 | 399 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1320 | 242 |
| Gabapentin | Gabapentin | 1071 | 264 |
| Pantoprazole Sodium | Pantoprazole Sodium | 816 | 179 |
| Potassium Chloride | Potassium Chloride | 763 | 177 |
| Metoprolol Succinate | Metoprolol Succinate | 722 | 151 |
| Amlodipine Besylate | Amlodipine Besylate | 675 | 175 |
| Farxiga | Dapagliflozin Propanediol | 614 | 135 |
| Atorvastatin Calcium | Atorvastatin Calcium | 609 | 149 |
| Mounjaro | Tirzepatide | 574 | 82 |
| Losartan Potassium | Losartan Potassium | 558 | 135 |
| Furosemide | Furosemide | 385 | 88 |
| Ezetimibe | Ezetimibe | 354 | 104 |
| Omeprazole | Omeprazole | 354 | 91 |
| Eliquis | Apixaban | 315 | 66 |
| Jardiance | Empagliflozin | 301 | 84 |
| Metformin Hcl Er | Metformin Hcl | 290 | 94 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 281 | 84 |
| Testosterone Cypionate | Testosterone Cypionate | 275 | 89 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 265 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 262 | 75 |
| Methylprednisolone | Methylprednisolone | 256 | 175 |
| Alprazolam | Alprazolam | 244 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 244 | 61 |
| Lisinopril | Lisinopril | 243 | 69 |
| Torsemide | Torsemide | 237 | 55 |
| Nifedipine Er | Nifedipine | 236 | 54 |
| Tramadol Hcl | Tramadol Hcl | 233 | 38 |
| Celecoxib | Celecoxib | 231 | 47 |
| Quetiapine Fumarate | Quetiapine Fumarate | 230 | 48 |
| Trazodone Hcl | Trazodone Hcl | 223 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 221 | 53 |
| Ozempic | Semaglutide | 216 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 215 | 45 |
| Famotidine | Famotidine | 214 | 51 |
| Azithromycin | Azithromycin | 209 | 157 |
| Ibuprofen | Ibuprofen | 200 | 67 |
| Meloxicam | Meloxicam | 198 | 52 |
| Ropinirole Hcl | Ropinirole Hcl | 198 | 38 |
| Sucralfate | Sucralfate | 193 | 55 |
| Linzess | Linaclotide | 188 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 183 | 62 |
| Metformin Hcl | Metformin Hcl | 173 | 50 |
| Paroxetine Hcl | Paroxetine Hcl | 170 | 28 |
| Allopurinol | Allopurinol | 165 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 163 | 32 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 160 | 35 |
| Mirtazapine | Mirtazapine | 158 | 30 |
| Memantine Hcl | Memantine Hcl | 157 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 156 | 48 |
| Carvedilol | Carvedilol | 155 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 152 | 30 |
| Synthroid | Levothyroxine Sodium | 145 | 23 |
| Atenolol | Atenolol | 138 | 32 |
| Tradjenta | Linagliptin | 134 | 26 |
| Baclofen | Baclofen | 131 | 33 |
| Tresiba Flextouch U-200 | Insulin Degludec | 130 | 31 |
| Xarelto | Rivaroxaban | 129 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 127 | 25 |
| Repatha Sureclick | Evolocumab | 126 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 126 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 125 | 35 |
| Sertraline Hcl | Sertraline Hcl | 125 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 124 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 124 | 26 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 124 | 37 |
| Montelukast Sodium | Montelukast Sodium | 121 | 29 |
| Prednisone | Prednisone | 120 | 54 |
| Clonidine Hcl | Clonidine Hcl | 117 | 46 |
| Colchicine | Colchicine | 117 | 38 |
| Donepezil Hcl | Donepezil Hcl | 113 | 20 |
| Vascepa | Icosapent Ethyl | 111 | 19 |
| Creon | Lipase/Protease/Amylase | 109 | 13 |
| Kerendia | Finerenone | 109 | 25 |
| Lorazepam | Lorazepam | 106 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 105 | 22 |
| Carisoprodol | Carisoprodol | 104 | 18 |
| Azelastine Hcl | Azelastine Hcl | 103 | 43 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 102 | 40 |
| Ondansetron Odt | Ondansetron | 102 | 27 |
| Clonazepam | Clonazepam | 101 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 101 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 100 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 99 | 31 |
| Midodrine Hcl | Midodrine Hcl | 98 | 21 |
| Propranolol Hcl Er | Propranolol Hcl | 97 | 16 |
| Glimepiride | Glimepiride | 96 | 21 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 92 | 29 |
| Pregabalin | Pregabalin | 92 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 91 | 58 |
| Januvia | Sitagliptin Phosphate | 90 | 21 |
| Trulicity | Dulaglutide | 89 | 16 |
| Naproxen | Naproxen | 88 | 15 |
| Spironolactone | Spironolactone | 87 | 23 |
| Eszopiclone | Eszopiclone | 86 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 85 | 26 |
| Myrbetriq | Mirabegron | 81 | 22 |
| Finasteride | Finasteride | 80 | 20 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 80 | 28 |
| Ranolazine Er | Ranolazine | 79 | 18 |
| Meclizine Hcl | Meclizine Hcl | 71 | 24 |
| Amiodarone Hcl | Amiodarone Hcl | 70 | 11 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 68 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 17 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 64 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 63 | 18 |
| Simvastatin | Simvastatin | 63 | 15 |
| Buspirone Hcl | Buspirone Hcl | 62 | 19 |
| Entresto | Sacubitril/Valsartan | 62 | 17 |
| Fluconazole | Fluconazole | 60 | 22 |
| Ibu | Ibuprofen | 60 | 24 |
| Modafinil | Modafinil | 60 | suppressed |
| Levetiracetam | Levetiracetam | 59 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 58 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 57 | 16 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 55 | 17 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 54 | 15 |
| Olanzapine | Olanzapine | 53 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 53 | 14 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 53 | 50 |
| Varenicline Tartrate | Varenicline Tartrate | 52 | 23 |
| Dexlansoprazole Dr | Dexlansoprazole | 49 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 49 | 13 |
| Methocarbamol | Methocarbamol | 49 | 20 |
| Vraylar | Cariprazine Hcl | 49 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 18 |
| Valacyclovir | Valacyclovir Hcl | 48 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 40 |
| Chlorthalidone | Chlorthalidone | 46 | 19 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 46 | suppressed |
| Mupirocin | Mupirocin | 45 | 34 |
| Promethazine Hcl | Promethazine Hcl | 45 | 14 |
| Bumetanide | Bumetanide | 44 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 44 | suppressed |
| Levofloxacin | Levofloxacin | 44 | 35 |
| Temazepam | Temazepam | 42 | suppressed |
| Cefprozil | Cefprozil | 41 | 28 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 39 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 39 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 39 | 19 |
| Gemtesa | Vibegron | 38 | suppressed |
| Tadalafil | Tadalafil | 37 | suppressed |
| Digoxin | Digoxin | 36 | suppressed |
| Glipizide | Glipizide | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Methotrexate | Methotrexate Sodium | 36 | suppressed |
| Clotrimazole | Clotrimazole | 35 | 22 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Febuxostat | Febuxostat | 34 | suppressed |
| Irbesartan | Irbesartan | 33 | suppressed |
| Loperamide | Loperamide Hcl | 33 | suppressed |
| Rybelsus | Semaglutide | 33 | suppressed |
| Telmisartan | Telmisartan | 33 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 32 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 32 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 32 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 20 |
| Risperidone | Risperidone | 32 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 32 | 11 |
| Aripiprazole | Aripiprazole | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 31 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 26 |
| Divalproex Sodium | Divalproex Sodium | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 29 | suppressed |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 28 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 22 |
| Colesevelam Hcl | Colesevelam Hcl | 26 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 26 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 26 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 26 | suppressed |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 26 | suppressed |
| Budesonide Dr | Budesonide | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 11 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 24 | 24 |
| Valsartan | Valsartan | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | 13 |
| Ramipril | Ramipril | 20 | suppressed |
| Timolol Maleate | Timolol Maleate | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Amantadine | Amantadine Hcl | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 17 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Praluent Pen | Alirocumab | 17 | suppressed |
| Xifaxan | Rifaximin | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | 14 |
| Haloperidol | Haloperidol | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | suppressed |
| Norethindrone | Norethindrone | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Invokana | Canagliflozin | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Nexletol | Bempedoic Acid | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Ramelteon | Ramelteon | 14 | suppressed |
| Dulera | Mometasone/Formoterol | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Silodosin | Silodosin | 13 | suppressed |
| Veozah | Fezolinetant | 13 | suppressed |
| Budesonide Ec | Budesonide | 12 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 12 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Motegrity | Prucalopride Succinate | 12 | suppressed |
| Olanzapine-Fluoxetine Hcl | Olanzapine/Fluoxetine Hcl | 12 | suppressed |
| Sulindac | Sulindac | 12 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Victoza 3-Pak | Liraglutide | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Epclusa | Sofosbuvir/Velpatasvir | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $892.26 · 33 records | Sekisui Diagnostics LLC | AIRSUPRA, CREON, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, GVOKE HYPOPEN, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, NUZYRA, OTEZLA, REPATHA, REXULTI, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VRAYLAR, WATCHMAN Access System, ZENPEP | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error